HopeStage
Back to all studies
WithdrawnNCT02929485

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

Medication studyAges 18–50United StatesAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 50 years.

Listed locations
Berkeley and 1 more locationSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateEstimated: July 2013
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
University of California, Berkeley
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 50 Years
Official registry ID
NCT02929485
Official title
Show the full official title

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

Recruitment & locations

Withdrawn

Berkeley · San Francisco

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of California, Berkeley, a university.

Does this study involve medication?

Yes. The study involves medication, including Tolcapone, Placebo and Bromocriptine.

Who can participate?

Listed age limits: 18 years to 50 years.

Is this study still recruiting?

The registry lists this study as withdrawn.

Want to explore more studies?

Explore studies